Close

Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/16/2024

1. SPY
2. TSLA
3. AMD
4. JNJ
5. ITCI
6. GS
7. BAC
8. MS
9. BK
10. UNH


Go back to Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)
(NASDAQ: CYTH) Delayed: 1.22 -0.02 (1.61%)
Previous Close $1.24    52 Week High $ 
Open $1.21    52 Week Low $ 
Day High $1.27    P/E N/A 
Day Low $1.11    EPS $ 
Volume 66,891